Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
J Biochem Mol Toxicol ; 35(1): e22629, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32935389

RESUMEN

Gestational diabetes mellitus is one of the causes of abnormal embryonic heart development, but the mechanism is still poor. This study investigated the regulatory mechanism and role of SOX11 in congenital heart abnormality in a hyperglycemic environment. Immunohistochemistry, Western blotting, and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed decreased SOX11 protein and messenger RNA (mRNA) levels in the heart tissue of diabetic offspring compared with the control group. A Sequenom EpiTYPER MassArray showed that methylation sites upstream in SOX11 region 1 were increased in the diabetic group compared with the control group. Luciferase reporter assays and qRT-PCR showed that Dnmt3b overexpression decreased SOX11 promoter activity and its mRNA level, whereas Dnmt3a had little effect on regulating SOX11 expression. Furthermore, we found that Dnmt3L cooperated with Dnmt3b to regulate SOX11 gene expression. Additionally, the function of SOX11 silencing was analyzed by using small interfering RNA-mediated knockdown. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and apoptotic assays showed that SOX11 downregulation inhibited cell viability and induced apoptosis in cardiomyocytes. Overexpression of the SOX11 gene suppressed cardiomyocytes apoptosis after high glucose treatment. We identified a novel epigenetic regulatory mechanism of SOX11 during heart development in a hyperglycemic environment and revealed a distinct role of SOX11 in mediating cardiomyocytes viability and apoptosis.


Asunto(s)
Apoptosis , Regulación hacia Abajo , Feto/metabolismo , Regulación del Desarrollo de la Expresión Génica , Hiperglucemia/embriología , Miocardio/metabolismo , Miocitos Cardíacos/metabolismo , Factores de Transcripción SOXC/biosíntesis , Animales , Femenino , Feto/patología , Hiperglucemia/patología , Masculino , Miocardio/patología , Miocitos Cardíacos/patología , Ratas , Ratas Sprague-Dawley
2.
Proc Natl Acad Sci U S A ; 115(40): 10142-10147, 2018 10 02.
Artículo en Inglés | MEDLINE | ID: mdl-30224493

RESUMEN

The primary stem cells of the cerebral cortex are the radial glial cells (RGCs), and disturbances in their operation lead to myriad brain disorders in all mammals from mice to humans. Here, we found in mice that maternal gestational obesity and hyperglycemia can impair the maturation of RGC fibers and delay cortical neurogenesis. To investigate potential mechanisms, we used optogenetic live-imaging approaches in embryonic cortical slices. We found that Ca2+ signaling regulates mitochondrial transport and is crucial for metabolic support in RGC fibers. Cyclic intracellular Ca2+ discharge from localized RGC fiber segments detains passing mitochondria and ensures their proper distribution and enrichment at specific sites such as endfeet. Impairment of mitochondrial function caused an acute loss of Ca2+ signaling, while hyperglycemia decreased Ca2+ activity and impaired mitochondrial transport, leading to degradation of the RGC scaffold. Our findings uncover a physiological mechanism indicating pathways by which gestational metabolic disturbances can interfere with brain development.


Asunto(s)
Señalización del Calcio , Corteza Cerebral/embriología , Diabetes Gestacional/metabolismo , Glucosa/metabolismo , Hiperglucemia/embriología , Neurogénesis , Neuroglía/metabolismo , Animales , Corteza Cerebral/patología , Diabetes Gestacional/genética , Diabetes Gestacional/patología , Femenino , Hiperglucemia/genética , Hiperglucemia/patología , Ratones , Ratones Transgénicos , Mitocondrias/genética , Mitocondrias/metabolismo , Mitocondrias/patología , Neuroglía/patología , Embarazo
3.
Cell Tissue Res ; 368(3): 563-578, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28283910

RESUMEN

Exposure to maternal diabetes during fetal growth is a risk factor for the development of type II diabetes (T2D) in later life. Discovery of the mechanisms involved in this association should provide valuable background for therapeutic treatments. Early embryogenesis involves epigenetic changes including histone modifications. The bivalent histone methylation marks H3K4me3 and H3K27me3 are important for regulating key developmental genes during early fetal pancreas specification. We hypothesized that maternal hyperglycemia disrupted early pancreas development through changes in histone bivalency. A human embryonic stem cell line (VAL3) was used as the cell model for studying the effects of hyperglycemia upon differentiation into definitive endoderm (DE), an early stage of the pancreatic lineage. Hyperglycemic conditions significantly down-regulated the expression levels of DE markers SOX17, FOXA2, CXCR4 and EOMES during differentiation. This was associated with retention of the repressive histone methylation mark H3K27me3 on their promoters under hyperglycemic conditions. The disruption of histone methylation patterns was observed as early as the mesendoderm stage, with Wnt/ß-catenin signaling being suppressed during hyperglycemia. Treatment with Wnt/ß-catenin signaling activator CHIR-99021 restored the expression levels and chromatin methylation status of DE markers, even in a hyperglycemic environment. The disruption of DE development was also found in mouse embryos at day 7.5 post coitum from diabetic mothers. Furthermore, disruption of DE differentiation in VAL3 cells led to subsequent impairment in pancreatic progenitor formation. Thus, early exposure to hyperglycemic conditions hinders DE development with a possible relationship to the later impairment of pancreas specification.


Asunto(s)
Diferenciación Celular , Endodermo/citología , Histonas/metabolismo , Hiperglucemia/embriología , Páncreas/embriología , Animales , Antígenos de Diferenciación/genética , Antígenos de Diferenciación/metabolismo , Azacitidina/farmacología , Línea Celular , Linaje de la Célula , Metilasas de Modificación del ADN/antagonistas & inhibidores , Metilasas de Modificación del ADN/metabolismo , Endodermo/metabolismo , Proteína Potenciadora del Homólogo Zeste 2/metabolismo , Inhibidores Enzimáticos/farmacología , Femenino , Regulación del Desarrollo de la Expresión Génica , Glucosa/farmacología , Humanos , Hiperglucemia/metabolismo , Masculino , Mesodermo/metabolismo , Metilación , Ratones , Ratones Endogámicos ICR , Páncreas/citología , Páncreas/metabolismo , Regiones Promotoras Genéticas , Transducción de Señal , Proteínas Wnt/metabolismo , beta Catenina/metabolismo
4.
Am J Obstet Gynecol ; 212(5): 569-79, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25434839

RESUMEN

Maternal diabetes-induced birth defects occur in 6-10% of babies born to mothers with pregestational diabetes, representing a significant maternal-fetal health problem. Currently, these congenital malformations represent a significant maternal-fetal medicine issue, but are likely to create an even greater public health threat as 3 million women of reproductive age (19-44 years) have diabetes in the United States alone, and this number is expected to double by 2030. Neural tube defects (NTDs) and congenital heart defects are the most common types of birth defects associated with maternal diabetes. Animal studies have revealed that embryos under hyperglycemic conditions exhibit high levels of oxidative stress resulting from enhanced production of reactive oxygen species and impaired antioxidant capability. Oxidative stress activates a set of proapoptotic kinase signaling intermediates leading to abnormal cell death in the embryonic neural tube, which causes NTD formation. Work in animal models also has revealed that maternal diabetes triggers a series of signaling intermediates: protein kinase C (PKC) isoforms, PKCα, ßII and δ; apoptosis signal-regulating kinase 1; c-Jun-N-terminal kinase (JNK)1/2; caspase; and apoptosis. Specifically, maternal diabetes in rodent models activates the proapoptotic unfolded protein response and endoplasmic reticulum (ER) stress. A reciprocal causation between JNK1/2 activation and ER stress exists in diabetic embryopathy. Molecular studies further demonstrate that deletion of the genes for Prkc, Ask1, Jnk1, or Jnk2 abolishes maternal diabetes-induced neural progenitor apoptosis and ameliorates NTD formation. Similar preventive effects are also observed when apoptosis signal-regulating kinase 1, JNK1/2, or ER stress is inhibited. Cell membrane stabilizers and antioxidant supplements are also effective in prevention of diabetes-induced birth defects. Mechanistic studies have revealed important insights into our understanding the cause of diabetic embryopathy and have provided a basis for future interventions against birth defects or other pregnancy complications associated with maternal diabetes. The knowledge of a molecular pathway map identified in animal studies has created unique opportunities to identify molecular targets for therapeutic intervention.


Asunto(s)
Apoptosis , Cardiopatías Congénitas/metabolismo , Hiperglucemia/metabolismo , Defectos del Tubo Neural/metabolismo , Estrés Oxidativo , Embarazo en Diabéticas/metabolismo , Proteínas Quinasas , Estrés del Retículo Endoplásmico , Femenino , Cardiopatías Congénitas/embriología , Humanos , Hiperglucemia/embriología , Defectos del Tubo Neural/embriología , Embarazo , Transducción de Señal
5.
Am J Obstet Gynecol ; 212(5): 650.e1-11, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25595579

RESUMEN

OBJECTIVE: Oxidative stress plays a causal role in diabetic embryopathy. Maternal diabetes induces heart defects and impaired transforming growth factor beta (TGFß) signaling, which is essential for cardiogenesis. We hypothesize that mitigating oxidative stress through superoxide dismutase 1 (SOD1) overexpression in transgenic (Tg) mice reverses maternal hyperglycemia-impaired TGFß signaling and its downstream effectors. STUDY DESIGN: Day 12.5 embryonic hearts from wild-type (WT) and SOD1 overexpressing embryos of nondiabetic (ND) and diabetic mellitus (DM) dams were used for the detection of oxidative stress markers: 4-hydroxynonenal (4-HNE) and malondlaldehyde (MDA), and TGFß1, 2, and 3, phosphor (p)-TGFß receptor II (TßRII), p-phosphorylated mothers against decapentaplegic (Smad)2, and p-Smad3. The expression of 3 TGFß-responsive genes was also assessed. Day 11.5 embryonic hearts were explanted and cultured ex vivo, with or without treatments of a SOD1 mimetic (Tempol; Enzo Life Science, Farmingdale, NY) or a TGFß recombinant protein for the detection of TGFß signaling intermediates. RESULTS: Levels of 4-HNE and MDA were significantly increased by maternal diabetes, and SOD1 overexpression blocked the increase of these 2 oxidative stress markers. Maternal diabetes suppresses the TGFß signaling pathway by down-regulating TGFß1 and TGFß3 expression. Consequently, phosphorylation of TßRII, Smad2, and Smad3, downstream effectors of TGFß, and expression of 3 TGFß-responsive genes were reduced by maternal diabetes, and these reductions were prevented by SOD1 overexpression. Treatment with Tempol or TGFß recombinant protein restored high-glucose-suppressed TGFß signaling intermediates and responsive gene expression. CONCLUSION: Oxidative stress mediates the inhibitory effect of hyperglycemia in the developing heart. Antioxidants, TGFß recombinant proteins, or TGFß agonists may have potential therapeutic values in the prevention of heart defects in diabetic pregnancies.


Asunto(s)
Corazón/embriología , Hiperglucemia/metabolismo , Miocardio/metabolismo , Estrés Oxidativo , Embarazo en Diabéticas/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo , Factor de Crecimiento Transformador beta2/metabolismo , Factor de Crecimiento Transformador beta3/metabolismo , Aldehídos/metabolismo , Animales , Femenino , Hiperglucemia/embriología , Malondialdehído/metabolismo , Ratones , Ratones Transgénicos , Fosforilación , Embarazo , Proteínas Serina-Treonina Quinasas/metabolismo , Receptor Tipo II de Factor de Crecimiento Transformador beta , Receptores de Factores de Crecimiento Transformadores beta/metabolismo , Transducción de Señal , Proteína Smad2/metabolismo , Proteína smad3/metabolismo , Superóxido Dismutasa/genética , Superóxido Dismutasa-1
6.
Reprod Biol Endocrinol ; 12: 80, 2014 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-25135621

RESUMEN

BACKGROUND: Fetal adaptations to high fat (HF) diet in utero (IU) that may predispose to Metabolic Syndrome (MetS) in adulthood include changes in fetal hepatic gene expression. Studies were performed to determine whether maternal exposure to HF diet at different stages during pregnancy had different effects on the fetus, including hepatic gene expression. METHODS: Female wild type mice were fed either a HF or breeding chow (C) for 2 wks prior to mating. The experimental groups were composed of embryonic day (e) 18.5 fetuses obtained from WT female mice that were fed HF (HF, 35.5% fat) or breeding chow (C, 9.5% fat) for 2 wk before mating until e9.5 of pregnancy (periconception-midpregnancy). At e9.5 dams were switched to the opposite diet (C-HF or HF-C). RESULTS: Exposure to HF diet throughout pregnancy reduced maternal weight gain compared to C diet (p < 0.02 HF vs. C). HF-C dams had significantly decreased adiponectin levels and litter size when compared to C-HF (p < 0.02 HF-C vs C-HF). Independent of the timing of exposure to HF, fetal weight and length were significantly decreased when compared to C diet (HF, C-HF and HF-C vs. C p < 0.02). HF diet during the second half of pregnancy increased expression of genes in the fetal liver associated with fetal growth (C-HF vs C p < 0.001), glucose production (C-HF vs C p < 0.04), oxidative stress and inflammation (C-HF vs C p < 0.01) compared to C diet. CONCLUSIONS: This model defines that there are critical periods during gestation in which the fetus is actively shaped by the environment. Early exposure to a HF diet determines litter size while exposure to HF during the second half of pregnancy leads to dysregulation of expression of key genes responsible for fetal growth, hepatic glucose production and oxidative stress. These findings underscore the importance of future studies designed to clarify how these critical periods may influence future risk of developing MetS later in life.


Asunto(s)
Dieta Alta en Grasa/efectos adversos , Desarrollo Fetal , Retardo del Crecimiento Fetal/etiología , Hiperglucemia/etiología , Fenómenos Fisiologicos Nutricionales Maternos , Síndrome Metabólico/etiología , Estrés Oxidativo , Adiponectina/sangre , Animales , Animales no Consanguíneos , Cruzamientos Genéticos , Femenino , Retardo del Crecimiento Fetal/inmunología , Retardo del Crecimiento Fetal/metabolismo , Peso Fetal , Regulación del Desarrollo de la Expresión Génica , Gluconeogénesis , Transportador de Glucosa de Tipo 4/genética , Hiperglucemia/embriología , Hiperglucemia/inmunología , Hiperglucemia/metabolismo , Tamaño de la Camada , Hígado/embriología , Hígado/inmunología , Hígado/metabolismo , Síndrome Metabólico/embriología , Síndrome Metabólico/inmunología , Síndrome Metabólico/metabolismo , Ratones Mutantes
7.
Am J Pathol ; 180(1): 153-64, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22056361

RESUMEN

Pregestational diabetes retards early embryonic growth. Placental and fetal growth are closely associated, suggesting that placental growth is also impaired. During the first trimester of gestation, oxygen tension rises steeply, leading to excessive production of reactive oxygen species (ROS), which is exacerbated in diabetes and may affect placental development. We hypothesized that oxygen modifies hyperglycemic effects on ROS formation, resulting in decreased first-trimester trophoblast growth. This was tested using a first trimester trophoblast-derived cell line (ACH-3P). Normoglycemia did not alter ACH-3P proliferation at 2.5%, 8%, and 21% oxygen. Hyperglycemic conditions for up to 3 days reduced cell number by 65% and resulted in cell cycle (G(1)- and S-phase) changes but only at 21% oxygen. Proliferation reduction could be partially restored by an inhibitor of mitogen-activated protein kinase (MAPK) ERK1/2 but not of Akt/PkB. Intracellular ROS elevation under hyperglycemia was oxygen independent, whereas mitochondrial superoxide levels were enhanced under hyperglycemia only at 21% oxygen. Intervention to modulate cytosolic and mitochondrial ROS, using ROS formation inducers and inhibitors, did not alter cell growth under hyperglycemia at 21% oxygen. The combination of hyperglycemia and high oxygen levels (21%) reduces proliferation of human first-trimester trophoblasts in a ROS-independent manner involving MAPK. This may account for reduced placental growth and, therefore, also for embryonic growth during the first-trimester pregestational diabetic pregnancies when the oxygen tension increases.


Asunto(s)
Diabetes Gestacional/fisiopatología , Hiperglucemia/embriología , Oxígeno/farmacología , Especies Reactivas de Oxígeno/metabolismo , Trofoblastos/fisiología , Antimetabolitos/farmacología , Antioxidantes/farmacología , Proliferación Celular , Células Cultivadas , Diabetes Gestacional/metabolismo , Inhibidores Enzimáticos/farmacología , Femenino , Humanos , Peróxido de Hidrógeno/metabolismo , Hiperglucemia/metabolismo , Hiperglucemia/fisiopatología , Sistema de Señalización de MAP Quinasas/fisiología , Mitocondrias/enzimología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Embarazo , Primer Trimestre del Embarazo , Inhibidores de Proteínas Quinasas/farmacología , Trofoblastos/metabolismo , Regulación hacia Arriba
8.
Clin Obstet Gynecol ; 56(3): 602-9, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23722920

RESUMEN

Fetal glucocorticoid overexposure is a key potential mechanism underlying the link between low birthweight and later life diseases. The fetus is protected from high maternal glucocorticoid levels by the placental enzyme 11ß-hydroxysteroid dehydrogenase type 2. Antenatal glucocorticoid administration to women at threat of preterm labor, and high endogenous maternal glucocorticoid levels during pregnancy associate with lower birthweight. Long-term consequences for offspring include hypothalamic-pituitary-adrenal axis activation, increased metabolic and cardiovascular disorders, and neurodevelopmental sequelae. Strategies are needed to limit antenatal glucocorticoid use to those most at risk of preterm labor and to identify those most at risk of future disease.


Asunto(s)
11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 2/fisiología , Enfermedades Cardiovasculares/embriología , Dislipidemias/embriología , Glucocorticoides/efectos adversos , Hiperglucemia/embriología , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Peso al Nacer/efectos de los fármacos , Enfermedades Cardiovasculares/inducido químicamente , Dislipidemias/inducido químicamente , Femenino , Desarrollo Fetal/efectos de los fármacos , Humanos , Hiperglucemia/inducido químicamente , Recién Nacido , Trabajo de Parto Prematuro , Embarazo , Efectos Tardíos de la Exposición Prenatal
9.
Reproduction ; 141(5): 607-15, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21367963

RESUMEN

Autophagy is critical to the process of development because mouse models have shown that lack of autophagy leads to developmental arrest during the pre-implantation stage of embryogenesis. The process of autophagy is regulated through signaling pathways, which respond to the cellular environment. Therefore, any alteration in the environment may lead to the dysregulation of the autophagic process potentially resulting in cell death. Using both in vitro and in vivo models to study autophagy in the pre-implantation murine embryo, we observed that the cells respond to environmental stressors (i.e. hyperglycemic environment) by increasing activation of autophagy in a differential pattern within the embryo. This upregulation is accompanied by an increase in apoptosis, which appears to plateau at high concentrations of glucose. The activation of the autophagic pathway was further confirmed by an increase in GAPDH activity in both in vivo and in vitro hyperglycemic models, which has been linked to autophagy through the activation of the Atg12 gene. Furthermore, this increase in autophagy in response to a hyperglycemic environment was observed as early as the oocyte stage. In conclusion, in this study, we provided evidence for a differential response of elevated activation of autophagy in embryos and oocytes exposed to a hyperglycemic environment.


Asunto(s)
Autofagia , Blastocisto/metabolismo , Glucosa/metabolismo , Hiperglucemia/metabolismo , Transducción de Señal , Estrés Fisiológico , Animales , Blastocisto/patología , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Técnicas de Cultivo de Embriones , Desarrollo Embrionario , Femenino , Gliceraldehído-3-Fosfato Deshidrogenasas/metabolismo , Hiperglucemia/embriología , Hiperglucemia/patología , Ratones , Oocitos/metabolismo , Oocitos/ultraestructura , Regulación hacia Arriba
10.
Birth Defects Res A Clin Mol Teratol ; 88(10): 791-803, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20890938

RESUMEN

This article provides an overview of the rationale for diabetes preconception care interventions for women with diabetes and the efficacy in reducing the excess occurrence of major congenital malformations. The problems with broad use of individualized preconception care are considered. In addition, suggestions are made for the implementation of more comprehensive interventions in the community and usual diabetes care settings, to address the multiple ongoing challenges in the prevention of structural anomalies associated with preexisting diabetes. Based on the published evidence, successful preconception care can be considered to include: achievement of individualized target standardized glycosylated hemoglobin levels, adequate nutrition, and minimizing hypoglycemia before and after discontinuing effective contraception and during the transition to early prenatal care.


Asunto(s)
Anomalías Congénitas/embriología , Anomalías Congénitas/prevención & control , Hiperglucemia/metabolismo , Atención Preconceptiva , Embarazo en Diabéticas , Diabetes Mellitus/metabolismo , Femenino , Hemoglobina Glucada/normas , Humanos , Hiperglucemia/embriología , Hipoglucemia/metabolismo , Embarazo , Atención Prenatal , Teratógenos/metabolismo , Mujeres
11.
Clin Sci (Lond) ; 114(5): 381-92, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17927565

RESUMEN

Substantial evidence suggests that poor intrauterine milieu elicited by maternal nutritional disturbance may programme susceptibility in the fetus to later development of chronic diseases, such as obesity, hypertension, cardiovascular disease and diabetes. One of the most interesting features of fetal programming is the evidence from several studies that the consequences may not be limited to the first-generation offspring and that it can be passed transgenerationally. In the present study, female rats (F0) were fed either a normal-protein diet [control diet (C); 19 g of protein/100 g of diet] or a low-protein diet [restricted diet (R); 5 g of protein/100 g of diet]. The offspring were termed according to the period and the types of diet the dams were fed, i.e. CC, RC, CR and RR (first letter indicates the diet during gestation and the second the diet during lactation). At 3 months of age, F1 females were bred to proven males, outside the experiment, to produce F2 offspring. At weaning, F2 offspring were divided by gender. RC1 offspring (with the number indicating the filial generation) were born with low birthweight, but afterwards they had catch-up growth, reaching the weight of the CC1 offspring. The increased glycaemia in RC1 offspring was associated with insulin resistance. CR1 and RR1 offspring had impaired growth with no changes in glucose metabolism. RC2 offspring had high BM (body mass) at birth, which was sustained over the whole experiment in male offspring. The F2 generation had more alteration in glucose metabolism than the F1 generation. CR2 and RC2 offspring had hyperglycaemia accompanied by hyperinsulinaemia and insulin resistance in both genders. CR2 offspring had an increase in body adiposity with hyperleptinaemia. In conclusion, low protein during gestation improves BM, fat mass and growth rate in F1 rats, but has adverse effects on glucose and leptin metabolism, resulting in insulin resistance in adult F1 and F2 offspring. Low protein during lactation has adverse effects on glucose, insulin and leptin metabolism, resulting in insulin resistance in adult F2 offspring. These findings suggest that low protein during gestation and/or lactation can be passed transgenerationally to the second generation.


Asunto(s)
Glucemia/metabolismo , Dieta con Restricción de Proteínas , Trastornos Nutricionales en el Feto/fisiopatología , Lactancia/fisiología , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Animales , Biometría , Femenino , Desarrollo Fetal/fisiología , Crecimiento/fisiología , Hiperglucemia/embriología , Hiperglucemia/genética , Hiperinsulinismo/embriología , Hiperinsulinismo/genética , Resistencia a la Insulina/genética , Resistencia a la Insulina/fisiología , Leptina/sangre , Masculino , Embarazo , Fenómenos Fisiologicos de la Nutrición Prenatal/fisiología , Ratas
12.
Clin Sci (Lond) ; 113(5): 219-32, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17663659

RESUMEN

Compelling epidemiological evidence suggests that exposure to an adverse intrauterine environment, manifested by low-birth weight, is associated with cardiometabolic and behavioural disorders in adulthood. These observations have led to the concept of 'fetal programming'. The molecular mechanisms that underlie this relationship remain unclear, but are being extensively investigated using a number of experimental models. One major hypothesis for early life physiological programming implicates fetal overexposure to stress (glucocorticoid) hormones. Several animal studies have shown that prenatal glucocorticoid excess, either from endogenous overproduction with maternal stress or through exogenous administration to the mother or fetus, reduces birth weight and causes lifelong hypertension, hyperglycaemia and behavioural abnormality in the offspring. Intriguingly, these effects are transmitted across generations without further exposure to glucocorticoids, which suggests an epigenetic mechanism. These animal observations could have huge implications if extrapolated to humans, where glucocorticoids have extensive therapeutic use in obstetric and neonatal practice.


Asunto(s)
Desarrollo Fetal/fisiología , Glucocorticoides/fisiología , Efectos Tardíos de la Exposición Prenatal , Estrés Psicológico , Adulto , Femenino , Humanos , Hiperglucemia/embriología , Hipertensión/embriología , Recién Nacido de Bajo Peso , Recién Nacido , Masculino , Embarazo
13.
Diabetes ; 51(9): 2804-10, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12196474

RESUMEN

Activation of the diacylglycerol-protein kinase C (DAG-PKC) cascade by excess glucose has been implicated in vascular complications of diabetes. Its involvement in diabetic embryopathy has not been established. We examined DAG production and PKC activities in embryos and decidua of streptozotocin (STZ)-diabetic or transiently hyperglycemic mice during neural tube formation. STZ diabetes significantly increased DAG and total PKC activity in decidua (1.5- and 1.4-fold, respectively) and embryos (1.7- and 1.3-fold, respectively) on day 9.5. Membrane-associated PKC alpha, betaII, delta, and zeta were increased in decidua by 1.25- to 2.8-fold. Maternal hyperglycemia induced by glucose injection on day 7.5, the day before the onset of neural tube formation, also increased DAG, PKC activity, and PKC isoforms (1.1-, 1.6-, and 1.5-fold, respectively) in the embryo on day 9.5. Notably, membrane-associated PKC activity was increased 24-fold in embryos of diabetic mice with structural defects. These data indicate that hyperglycemia just before organogenesis activates the DAG-PKC cascade and is correlated with congenital defects.


Asunto(s)
Diglicéridos/biosíntesis , Embarazo en Diabéticas/embriología , Proteína Quinasa C/metabolismo , Animales , Decidua/metabolismo , Embrión de Mamíferos/metabolismo , Desarrollo Embrionario y Fetal , Femenino , Feto/metabolismo , Hiperglucemia/embriología , Ratones , Ratones Endogámicos ICR , Sistema Nervioso/embriología , Embarazo , Factores de Tiempo
14.
Diabetes ; 35(9): 964-72, 1986 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-2943621

RESUMEN

Fetal insulin secretion may be of importance in determining both fetal metabolic rate and glucose homeostasis in the resting state. To investigate this question, streptozocin (STZ) was injected into 10 late-gestation fetal lambs, and the effects of STZ on fetal pancreatic insulin storage and secretion, fetal metabolic rate, and umbilical glucose uptake were then studied. Fetal STZ injection caused a relative fetal hyperglycemia by 24 h after injection. Fetal hyperglycemia reached a maximum by 72 h and persisted for at least 10 days after injection. Neonates delivered after fetal injection were frankly diabetic. Fetal STZ injection was associated with complete suppression of both glucose- and tolbutamide-stimulated insulin release, although no changes in peripheral insulin concentration were observed when compared with controls. Fetal pancreatic insulin content was only 13% of that expected on the basis of gestational age. In a subgroup of 7 STZ-treated fetal lambs, fetal hyperglycemia was related to decrements in umbilical venoarterial difference of glucose, umbilical glucose uptake, and glucose-O2 quotient. No changes in maternal glucose homeostasis or in fetal O2 consumption were noted. The data suggest that deficient fetal insulin storage and secretion are associated with a decrement in exogenous fetal glucose entry but not in fetal metabolic rate. Whether the observed fetal changes relate to enhanced endogenous fetal glucose production with a passive decrease in maternofetal glucose transfer or are simply due to a decrease in overall fetal glucose utilization is not known. It is speculated that a quantitative decrease in pancreatic insulin secretion is responsible for the observed changes.


Asunto(s)
Feto/metabolismo , Insulina/metabolismo , Animales , Animales Recién Nacidos/metabolismo , Animales Recién Nacidos/fisiología , Glucemia/análisis , Diabetes Mellitus Experimental/fisiopatología , Sangre Fetal/análisis , Feto/fisiología , Hiperglucemia/embriología , Insulina/sangre , Secreción de Insulina , Islotes Pancreáticos/embriología , Islotes Pancreáticos/metabolismo , Ovinos/embriología , Estreptozocina/farmacología , Tolbutamida/farmacología
15.
Diabetes ; 34 Suppl 2: 32-5, 1985 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-3888739

RESUMEN

Maternal or fetal substrate infusions into chronically catheterized fetal lambs have recently been performed in order to examine the effects of excessive fetal substrate presentation on fetal metabolism and metabolic rate. The degree of maternal hyperglycemia in this animal model has been shown to relate to the degree of fetal hyperglycemia and to the magnitude of fetal glucose utilization. Series of direct fetal glucose infusions were performed designed to mimic the development of moderate maternal hyperglycemia. These studies suggest that fetal glucose excess stimulates fetal oxidative metabolism with increases in fetal glucose and lactate entry and stimulation of fetal oxygen consumption. If severe, fetal lamb hyperglycemia may result in fetal hypoxia with metabolic acidosis and fetal demise. The metabolic goal of the stimulation of fetal oxidation may relate to increases in fetal activity such as respiration, excessive fetal growth, and other factors, as yet unidentified. Insulin or catecholamines may be mediators of at least some of these events. Chronic infusion studies regarding other potential fetal fuels have not yet been performed. The chronically catheterized glucose-infused fetal lamb may offer insights into the metabolic derangements observed and suspected in infants born to women with gestational and insulin-requiring diabetes mellitus.


Asunto(s)
Feto/metabolismo , Glucosa/farmacología , Embarazo en Diabéticas/metabolismo , Animales , Glucemia/metabolismo , Modelos Animales de Enfermedad , Femenino , Sangre Fetal/metabolismo , Hipoxia Fetal/etiología , Feto/efectos de los fármacos , Hiperglucemia/complicaciones , Hiperglucemia/embriología , Insulina/sangre , Lactatos/metabolismo , Ácido Láctico , Consumo de Oxígeno/efectos de los fármacos , Embarazo , Ovinos
16.
Diabetes Care ; 25(12): 2287-91, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12453975

RESUMEN

OBJECTIVE: In animals, experimentally induced maternal hyperglycemia during pregnancy results in hyperglycemic offspring. Similarly, Pima Indian offspring with mothers who are diabetic at the time of pregnancy have increased risk of early-onset diabetes. We hypothesized that exposure to hyperglycemia in utero would decrease the age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY) due to a mutation in the hepatocyte nuclear factor 1alpha (HNF-1alpha) gene. RESEARCH DESIGN AND METHODS: We analyzed the affect of maternal diabetes on age at diagnosis of diabetes in 150 HNF-1alpha gene mutation carriers from 55 families. RESULTS: Age at diagnosis in HNF-1alpha mutation carriers was younger when the mother was diagnosed before pregnancy compared with when the mother was diagnosed after pregnancy (15.5 +/- 5.4 vs. 27.5 +/- 13.1 years, P < 0.0001). This is unlikely to represent a generalized familial decrease in age at diagnosis due to a more severe mutation, because no difference was seen in age of the offspring at diagnosis of diabetes when the father was diagnosed at a young age, and a similar trend was seen when only the single common mutation, P291fsinsC, was analyzed. CONCLUSIONS: We conclude that maternal hyperglycemia during pregnancy probably increases the penetrance of HNF-1alpha mutations. The potential role of exposure to hyperglycemia in utero in a monogenic diabetic subgroup warrants prospective study.


Asunto(s)
Proteínas de Unión al ADN , Diabetes Mellitus/genética , Diabetes Gestacional/genética , Hiperglucemia/embriología , Mutación , Proteínas Nucleares , Factores de Transcripción/genética , Adulto , Edad de Inicio , Diabetes Mellitus/diagnóstico , Femenino , Tamización de Portadores Genéticos , Impresión Genómica , Factor Nuclear 1 del Hepatocito , Factor Nuclear 1-alfa del Hepatocito , Factor Nuclear 1-beta del Hepatocito , Humanos , Masculino , Estado Prediabético/genética , Embarazo , Eliminación de Secuencia
17.
J Endocrinol ; 170(3): 653-60, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11524246

RESUMEN

In a previous study, we showed that exposure of rats to dexamethasone (Dex) selectively in late pregnancy produces permanent induction of hepatic phosphoenolpyruvate carboxykinase (PEPCK) expression and hyperglycaemia in the adult offspring. The mechanisms by which glucocorticoids cause this programming are unclear but may involve direct actions on the fetus/neonate, or glucocorticoids may act indirectly by affecting maternal postnatal nursing behaviour. Using a cross-fostering paradigm, the present data demonstrate that switching the offspring at birth from Dex-treated dams to control dams does not prevent induction of PEPCK or hyperglycaemia. Similarly, offspring born to control dams but reared by Dex-treated dams from birth maintain normal glycaemic control. During the neonatal period, injection of saline per se was sufficient to cause exaggeration in adult offspring responses to an oral glucose load, with no additional effect from Dex. However, postnatal treatment with either saline or Dex did not alter hepatic PEPCK activity. Prenatal Dex permanently raised basal plasma corticosterone levels, but under stress conditions there were no differences in circulating corticosterone levels. Likewise, Dex-exposed rats had similar plasma catecholamine concentrations to control animals. These findings show that glucocorticoids programme hyperglycaemia through mechanisms that operate on the fetus or directly on the neonate, rather than via effects that alter maternal postnatal behaviour during the suckling period. The hyperglycaemic response does not appear to result from abnormal sympathoadrenal activity or hypothalamic-pituitary-adrenal response during stress.


Asunto(s)
Dexametasona/farmacología , Feto/efectos de los fármacos , Glucocorticoides/farmacología , Hiperglucemia/embriología , Efectos Tardíos de la Exposición Prenatal , Animales , Peso al Nacer/efectos de los fármacos , Corticosterona/sangre , Epinefrina/sangre , Femenino , Prueba de Tolerancia a la Glucosa , Intercambio Materno-Fetal , Norepinefrina/sangre , Embarazo , Proteínas Serina-Treonina Quinasas/metabolismo , Ratas , Ratas Wistar , Estrés Fisiológico/sangre , Aumento de Peso/efectos de los fármacos
18.
Metabolism ; 39(3): 220-4, 1990 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-2106606

RESUMEN

Animal models of diabetes mellitus during pregnancy have repeatedly suggested that maternal hyperglycemia was teratogenic during organogenesis, and thus may contribute to diabetic teratogenesis. However, little attention has been focused on the effects of hyperglycemia on pre-organogenic development. In this report, we examine the effect of hyperglycemia (950 mg glucose/dL) on the development of mouse pre-embryos in vitro. B6C3F1 mice were superovulated with 5 U pregnant mare serum gonadotropin (PMSG) followed by 5 U human chorionic gonadotropin (hCG) 48 hours later. Two cell pre-embryos were recovered 48 hours later, pooled together, and randomly assigned to different treatment groups. Cultures were performed in HAM's F-10 media (Gibco, Long Island, NY) with 0.1% bovine serum albumin (BSA; Sigma, St. Louis, MO) BSA at 37 degrees C in an atmosphere of 5% CO2, 5% O2, and 90% N2 with 15 to 30 embryos per milliliter of culture fluid. Cultures were viewed daily at 24, 48, and 72 hours after culturing, with recording of the development. Compared with control pre-embryos (n = 216), embryos cultured in elevated glucose levels (950 mg/dL) (n = 226) demonstrated marked growth retardation as assessed both by (1) distribution of developmental stages at each observation point (24 hours, P less than .001; 48 hours, P less than .006; 72 hours, P less than .001); and (2) a difference in the average rank sums indicating a delay in maturation (P less than .005). In a second protocol group, pre-embryos were cultured in an equivalent amount of L-glucose; no impairment in development compared with controls was noted.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Embrión de Mamíferos/embriología , Hiperglucemia/embriología , Embarazo en Diabéticas/embriología , Animales , Ácido Araquidónico , Ácidos Araquidónicos/farmacología , Blastocisto/citología , Blastómeros/citología , Células Cultivadas/efectos de los fármacos , Desarrollo Embrionario y Fetal , Femenino , Glucosa/farmacología , Hiperglucemia/complicaciones , Ratones , Óvulo/citología , Embarazo , Embarazo en Diabéticas/metabolismo , Factores de Tiempo
19.
Exp Diabetes Res ; 2012: 565160, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23133443

RESUMEN

The incidence of gestational diabetes is increasing worldwide, exposing large numbers of infants to hyperglycaemia whilst in utero. This exposure may have a long-term negative impact on the cardiovascular health of the offspring. Novel methods to assess cardiovascular status in the neonatal period are now available-including measuring arterial intima-media thickness and retinal photography. These measures will allow researchers to assess the relative impact of intrauterine exposures, distinguishing these from genetic or postnatal environmental factors. Understanding the long-term impact of the intrauterine environment should allow the development of more effective health policy and interventions to decrease the future burden of cardiovascular disease. Initiating disease prevention aimed at the developing fetus during the antenatal period may optimise community health outcomes.


Asunto(s)
Enfermedades Cardiovasculares/etiología , Diabetes Mellitus Tipo 2/fisiopatología , Diabetes Gestacional/fisiopatología , Salud de la Familia , Desarrollo Fetal , Hiperglucemia/embriología , Embarazo en Diabéticas/fisiopatología , Animales , Aterosclerosis/epidemiología , Aterosclerosis/etiología , Enfermedades Cardiovasculares/epidemiología , Diabetes Mellitus Tipo 2/sangre , Diabetes Gestacional/sangre , Susceptibilidad a Enfermedades , Femenino , Humanos , Hiperglucemia/etiología , Hiperglucemia/fisiopatología , Masculino , Intercambio Materno-Fetal , Obesidad/epidemiología , Obesidad/etiología , Obesidad/fisiopatología , Embarazo , Embarazo en Diabéticas/sangre , Riesgo
20.
Folia Histochem Cytobiol ; 49(2): 325-34, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21744335

RESUMEN

In various tissues, glucocorticoids (GCs) are known to downregulate glucose transport systems; however, their effects on glucose transporters (GLUTs) in the placenta of a diabetic rat are unknown. Glucocorticoid hormone action within the cell is regulated by the glucocorticoid receptor (GR). Thus, this study was designed to investigate the relationship between GR and glucose transporter expression in the placenta of the diabetic rat. Our immunohistochemical results indicated that GR and glucose transporter protein 1 (GLUT 1) are expressed ubiquitously in the trophoblast and endothelial cells of the labyrinthine zone, where maternal fetal transport takes place in the rat placenta. Expression of GR in the junctional zone of the rat placenta was detected in giant cells, and in some spongiotrophoblast cells, but not in the glycogen cells. GLUT 1 was present, especially in glycogen cells during early pregnancy, and in the spongiotrophoblast cells of the junctional zone during late pregnancy. Amounts of GR and GLUT 1 protein were increased towards the end of gestation both in the control and the diabetic placenta. However, at days 17 and 19 of gestation, only the placental GR protein was significantly increased in the streptozotocin-induced diabetic rats compared to control rats. Diabetes led to a significant decrease in placental weight at gestation day 15. In contrast, at gestational days 17 and 21, the weights of the diabetic placenta were significantly increased as compared with the controls. Moreover, diabetes induced fetus intrauterine growth retardation at gestational days 13, 17 and 21. In conclusion, the localization pattern of GR and GLUT 1 proteins in the same cell types led us to believe that there might be a relationship between GR and GLUT 1 expressions at the cellular level. GLUT 1 does not play a pivotal role in diabetic pregnancies. However, placental growth abnormalities during diabetic pregnancy may be related to the amount of GR.


Asunto(s)
Diabetes Mellitus Experimental/embriología , Diabetes Mellitus Experimental/metabolismo , Transportador de Glucosa de Tipo 1/metabolismo , Placenta/embriología , Placenta/metabolismo , Receptores de Glucocorticoides/metabolismo , Animales , Glucemia/metabolismo , Peso Corporal , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/complicaciones , Femenino , Feto/metabolismo , Hiperglucemia/sangre , Hiperglucemia/complicaciones , Hiperglucemia/embriología , Immunoblotting , Inmunohistoquímica , Placenta/patología , Embarazo , Transporte de Proteínas , Ratas , Estreptozocina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA